Gary Hattersley, Ph.D., serves as the Chief Scientific Officer at NUVATION BIO INC CLASS A, a biopharmaceutical company focused on developing innovative therapies for cancer. Dr. Hattersley brings a wealth of experience in drug discovery and development, particularly in the field of oncology. He holds a Ph.D. in Biochemistry from the University of Leeds, UK, and has spent over two decades in the biopharmaceutical industry, contributing significantly to the advancement of novel therapeutics. Prior to joining NUVATION BIO, Dr. Hattersley held key leadership positions at several prominent biotech companies. He was instrumental in the development of several successful drug candidates, including a notable contribution to the discovery and development of a groundbreaking cancer therapy while at his previous company. His expertise in translational research and his strategic vision have been pivotal in guiding NUVATION BIO's scientific direction. At NUVATION BIO, Dr. Hattersley leads the company's research and development efforts, overseeing a talented team of scientists and researchers dedicated to bringing new cancer treatments to patients. In his role as Chief Scientific Officer, Dr. Hattersley is responsible for driving the company's pipeline of innovative drug candidates. His leadership has been crucial in advancing NUVATION BIO's mission to transform the treatment landscape for cancer patients. Dr. Hattersley's commitment to scientific excellence and his passion for improving patient outcomes continue to drive the company's success in the competitive field of oncology drug development.